BPC 157 is a recurring topic in our peptide coverage. This hub collects every article tagged BPC 157, newest first, each evidence-graded and tied to real, verifiable sources.
An evidence-first ranking of the peptides studied for inflammatory bowel disease — BPC-157, KPV, thymosin alpha-1 and larazotide acetate — separating decades of rodent colitis data from the near-total absence of human IBD trials.
An evidence-first ranking of the peptides studied for IBS — the FDA-approved GC-C agonists linaclotide and plecanatide, plus larazotide, BPC-157 and KPV — separating real human trials from preclinical promise and marketing hype.
An evidence-graded review of the peptides marketed for hip labral tears, femoroacetabular impingement, gluteal tendinopathy (GTPS) and hip bursitis. The honest 2026 verdict: no peptide has a human hip trial — the evidence tops out at animal models, while exercise and PRP hold the real human RCT data.
A clinical, evidence-graded ranking of the peptides studied for bone — from the FDA-approved PTH-class anabolics with Grade A fracture-prevention RCTs to the entirely preclinical regenerative peptides.
A clinical, evidence-first look at the peptides pitched for lateral and medial epicondylitis — BPC-157 and TB-500/thymosin β-4 — and why both are graded C (preclinical only) for the elbow.
An evidence-graded review of the peptides marketed for cartilage and meniscus repair. The honest 2026 verdict: no peptide has a placebo-controlled human trial showing cartilage regrowth or meniscus repair, and the only controlled human data belongs to pentosan polysulfate — which is not even a peptide.
A clinical, evidence-graded review of the five peptides marketed for cardiovascular and heart health — elamipretide, angiotensin-(1-7), thymosin β4, TB-500 and BPC-157 — separating real human trials from preclinical and marketing claims.
LL-37, GHK-Cu, thymosin β4/TB-500 and BPC-157 all have real wound-healing biology — but not a single controlled human burn trial. A clinical-editorial ranking of what the evidence actually supports in 2026.
A clinical, evidence-ranked look at the peptides marketed for back injury, spinal soft-tissue repair, and disc health — what the published data actually supports, and what is marketing.
An evidence-graded review of the peptides marketed for athletic recovery — BPC-157, ipamorelin, CJC-1295 and TB-500. The honest 2026 verdict: every one is Grade C or D for recovery as an outcome, none is FDA-approved, and all are WADA-banned at all times.
An evidence-graded review of the peptides marketed for ankle sprains, ATFL tears and Achilles injury. The honest 2026 verdict: no human RCT exists; the strongest case is preclinical (rat Achilles models), and PRP — not a peptide — has the better human ankle evidence.
A clinical monograph on Pentadeca Arginate (PDA) — the L-arginine salt of BPC-157 marketed for tendon, gut and wound healing. Zero PDA-specific studies, borrowed preclinical data, and an unsettled 2026 legal status.
A clinical monograph on Pentadeca Arginate — the L-arginine salt of BPC-157. No studies exist under the 'PDA' name; the borrowed parent evidence is 35:1 preclinical, with zero human RCTs and an unsettled 2026 legal status.
A clinical monograph on the arginate (di-L-arginine) salt of BPC-157 — the same peptide with an arginine counterion. The storage and gastric-acid stability advantage is real; the headline oral-bioavailability claims are unproven marketing.
A clinical monograph on BPC-157 — the stable gastric pentadecapeptide marketed for tendon, gut and wound healing. Deep preclinical data, no completed human RCT, and an unsettled 2026 legal status.
BPC 157 is a topic our editors cover across the site. This hub aggregates the related, evidence-graded guidance.
This hub updates automatically whenever a new article is tagged BPC 157, so the latest coverage appears first.
Yes. Every article here grades its efficacy claims A-D and cites real, verifiable studies, regulatory documents or trial registries.
The majority of compounds documented here are not approved by the FDA for human use. Approved drugs (e.g. semaglutide, tirzepatide) are noted explicitly and require a licensed prescriber.
Many peptides — including BPC-157 and GHK-Cu in injectable form — are sold strictly "for research use only — not for human consumption." Purity, identity, and dosing of such products are not regulated or guaranteed.
Several compounds are banned in competitive sport under the WADA Prohibited List. Athletes risk sanction regardless of intent or formulation.
Always consult a qualified, licensed healthcare professional before considering any compound. Individual risk depends on your full medical context.
This content is for informational and educational purposes only · No physician–patient relationship is created · Evidence grades reflect published data as of the stated revision and may change.